close
MENU
How to guide
How to guide
Home
The NBR List
NBR View
NBR Marketplace

Categories

Australia Business Comings and Goings Economics Investment Law NZ Aviation News Politics Professional Services Property Retail Tech & Innovation

Analysis

All Economy Matters Edwards on Politics Hunter’s Corner Last Word Margin Call On the Money Shoeshine Underarm NBR Focus

Featured

NBR View Audio Articles Entrepreneurs Your Business Beehive Banter Morning Brew Toil & Trouble NZ Aviation News Back Issues Market Outlook Dollars & Sense Private Bin Opinion (Archive) NBR Radar (Archive) NBR Rich List (Archive)
Investment
4 mins to read

AFT mulls appeal after adverse court ruling

The listed health company does not expect a material effect on 2024 earnings guidance.

AFT Pharmaceuticals and its managing director Hartley Atkinson decided to defend the claim back in 2020.

Kate McVicar Tue, 29 Aug 2023

AFT Pharmaceuticals is considering the impact of a High Court judgment that could see 35% of profits from a drug under development go toward a subsidiary's shareholder. 

Yesterday, the Auckland High Court upheld ‘parts’ of claims against publicly listed AFT Pharmaceuticals lodged by

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
View terms and conditions.
Individual
Group membership
NBR Marketplace
NZ Aviation News

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Aviation News - Monthly

NZ$14.95 / monthly

Already have an account? Login
Kate McVicar Tue, 29 Aug 2023
Contact the Writer: kate@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Tags
AFT Pharmaceuticals AFT Law
Company profile
Powered by:
Change:
Price
Previous Close
Turnover
Movement
Volume
Avg Daily Volume
Daily High
Daily Low
52 Week High
52 Week Low
Related News
Tech & Innovation

AFT Pharmaceuticals hopes to get US Maxigesic sales by early 2024
Investment

AFT lowers full-year earnings guidance despite sales surge
Investment

AFT’s core Australian business under-appreciated, analysts say
Investment

AFT poised for new product launches in New Zealand and abroad

Business

Why Kiwi drug maker is not calling it quits on Pascomer
Law

AFT Pharm sued over Pascomer drug
Company profile
Powered by:
Change:
Price
Previous Close
Turnover
Movement
Volume
Avg Daily Volume
Daily High
Daily Low
52 Week High
52 Week Low
Related News
Tech & Innovation

AFT Pharmaceuticals hopes to get US Maxigesic sales by early 2024
Investment

AFT lowers full-year earnings guidance despite sales surge
Investment

AFT’s core Australian business under-appreciated, analysts say
Investment

AFT poised for new product launches in New Zealand and abroad

Business

Why Kiwi drug maker is not calling it quits on Pascomer
Law

AFT Pharm sued over Pascomer drug
AFT mulls appeal after adverse court ruling
Investment,
100627
true
Subscribe Login